Drug Trial Radar · NCT01014741
Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation
Last checked: Nov 19, 2026Latest source record: Feb 14, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
200
Actual
Start
Oct 2009
Primary completion
Jan 2015
Study completion Jan 2015
Sponsor
- Lead sponsor
- Vivek ReddyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Abbott Medical Devices
- First posted
- Nov 17, 2009
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Procedures for ablation of persistent or long lasting atrial fibrillation are frequently long and require extensive ablation. Some electrophysiologists administer the drug ibutilide during these procedures to help organize the fibrillatory activity of the left atrium with the hope that this may shorten the length of the procedure and duration of ablation needed. Currently there is no standardized approach of administering the drug ibutilide during these procedures, thus the investigators cannot be certain that administering this drug does in fact facilitate the procedure. The aim of the MAGIC-AF Trial is to see if administering a standard dose of the drug ibutilide at a standard time in the procedure can allow for a reduction in the ablation procedure time. The investigators hypothesize that administering ibutilide during these procedures will result in a reduction in the procedure and ablation time required.
Conditions
- Persistent Atrial Fibrillation
Interventions
IbutilideDrug
0.25mg IV ibutilide after PV isolation prior to CFE ablation
PlaceboDrug
Placebo after PV isolation prior to CFE ablation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With 1 Year Freedom From AF / ATTime frame: one year
Locations
7 sites in 3 countries. Site status is shown where the registry gives one.
Regional Cardiology Associates
Sacramento, California
Massachusetts General Hospital
Boston, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts
Icahn School of Medicine at Mount Sinai
New York, New York
University Of Virginia Health System
Charlottesville, Virginia
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Republic of Korea University Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.